Andere Sprachen Xspray Pharma AB

Aktien

A2H48J

SE0009973563

XSPRAY

Biotechnologie

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 18:00:00 19.06.2025			% 5 Tage	% 1. Jan.
39,55 ^SEK	+2,33 %		+11,41 %	-4,58 %

15.05.	Xspray Pharma erwartet FDA-Entscheidung zu Dasynoc im Oktober – bereitet Markteinführung vor	FW
14.05.	US-Arzneimittelbehörde FDA nimmt erneut eingereichten NDA von Xspray Pharma entgegen	CI

Andere Sprachen

FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc®	14.05.
U.S. Food and Drug Administration Achieves Receipt of Xspray Pharma's Re-Submitted NDA	14.05.
Bulletin from the annual general meeting of Xspray Pharma AB (publ)	13.05.
Xspray Pharma AB Appoints Markus Haeberlein and Anne Prener as New Members of the Board of Directors	13.05.
Xspray Pharma Q1 2025 - All eyes on PDUFA	08.05.
Interim Report First Quarter 2025	07.05.
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2025	07.05.
Notice of annual general meeting of Xspray Pharma AB (publ)	10.04.
Xspray Pharma Files Revised Application with US FDA for Leukemia Drug	08.04.
Xspray Pharma Re-Submits FDA Application	08.04.
Xspray Pharma re-submits its FDA application	08.04.
Xspray Pharma AB Re-Submits its FDA Application	08.04.
Xspray Pharma AB publishes its Annual Report for 2024	27.03.
Xspray Pharma AB Auditor Raises 'Going Concern' Doubt	27.03.
Certain Oridnary Shares of Xspray Pharma AB are subject to a Lock-Up Agreement Ending on 2-MAR-2025.	02.03.
Xspray Pharma Q4 2024 - In anticipation of an eventful year	13.02.
Interim Report Fourth Quarter 2024	12.02.
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	12.02.
Xspray Pharma : reports strong interim data for product candidate XS003 - confirms plan to apply for market approval in H1 2025	20.01.
Xspray Pharma reports strong interim data for product candidate XS003 – confirms plan to apply for market approval in H1 2025	20.01.
Xspray Pharma AB Reports Strong Interim Data for Product Candidate XS003 - Confirms Plan to Apply for Market Approval in First Half 2025	20.01.
New number of shares and votes in Xspray Pharma after rights issue	30.12.
Xspray publishes the final outcome of the rights issue	04.12.
Xspray Pharma Raises SEK135 Million Via Rights Issue	02.12.
Xspray Pharma : Strong interest in Xspray Pharma AB's rights issue - preliminary outcome is published	02.12.

Keine Ergebnisse zu dieser Suche

Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Xspray Pharma AB

Aktien

A2H48J

SE0009973563

XSPRAY

Biotechnologie

Andere Sprachen

Filter